ArticleHaemophilia : the official journal of the World Federation of Hemophilia
Real-World Unmet Treatment Needs for Patients With Haemophilia: Results From the Global Adelphi Disease Specific Programme Database.
Article in Haemophilia : the official journal of the World Federation of Hemophilia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionProphylactic factor replacement and non-factor therapy has improved bleed prevention and clinical outcomes for people with haemophilia (PwH). The remaining burdens faced by PwH in real-world settings, despite availability of newer therapies, are not well documented.
aimWe aimed to describe the haemophilia patient population, assess clinical and humanistic burden of disease, and identify unmest needs associated with current treatments.
methodsData were drawn from the Adelphi Real World Haemophilia Disease Specific Programme, a cross-sectional survey of haemophilia-treating physicians, their patients with haemophilia A (HA) or B (HB), and caregivers. Data were collected in multiple countries from July 2023 to October 2024. Physicians reported patient demographics, disease characteristics, treatment details, bleeding episodes and joint health status. Patients and caregivers reported health-related quality of life (HRQoL). Analyses were descriptive.
resultsOverall, 283 physicians reported on 2227 patients, with 67% of PwH aged 18-49 years. Prophylactic compliance was high: 94% of patients were either fairly or fully compliant (taking 50%-80% or >80% of prescribed dose, respectively). However, physicians were not completely satisfied with prophylaxis for 56% of patients with HA and 59% with HB, citing concerns about administration methods, dosing schedules, and efficacy. Joint problems were experienced by 49% of patients; 57% reported ≥1 bleed annually despite prophylaxis. HRQoL impairment was reported by patients on all types of prophylaxis.
conclusionDespite current treatment, many PwH continue to experience limitations to their daily activities, productivity, and physical independence. A patient-centred approach is needed to ensure clinical effectiveness can be balanced with lifestyle priorities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.